GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ATL-001

Company
Atlas Molecular Pharma
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for ATL-001 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07024316

    A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

    Not yet reported, Not yet reported Atlas Molecular Pharma 6 participants Est. completion 2028-06-01 1 site Stand-alone
    Other conditions: Congenital Erythropoietic Porphyria (CEP)
    View official trial listing →
  • Terminated NCT NCT03997474

    ATL001 in Patients With Metastatic or Recurrent Melanoma

    Not yet reported, Not yet reported Achilles Therapeutics UK Limited 13 participants Est. completion 2024-09-03 10 sites
    Other conditions: Melanoma
    View official trial listing →
  • Terminated NCT NCT04032847

    ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

    Not yet reported, Not yet reported Achilles Therapeutics UK Limited 27 participants Est. completion 2024-09-26 19 sites
    Other conditions: Advanced Non Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT04785365

    Long-Term Follow-Up Study of Patients Receiving ATL001

    Not yet reported Achilles Therapeutics UK Limited 1 participants Est. completion 2023-10-18 1 site
    Other conditions: Melanoma, Advanced Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT05647343

    Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

    Not yet reported Atlas Molecular Pharma 42 participants Est. completion 2024-04-08 1 site Stand-alone
    Other conditions: Adverse Effect of Drugs and Medicaments in Therapeutic Use
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: ATL-001, ATL-001 (Ciclopirox oral solution)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.